KDR and neoplasm: Surufatinib provides a biological basis for the synergistic effect of ICI and chemotherapeutic agents by inhibiting VEGFR, FGFR, and CSF-1R, exerting anti-angiogenesis and regulating the tumor microenvironment (7, 12).